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A monoclonal antibody to Siglec-8 suppresses non-allergic
airway inflammation and inhibits IgE-independent mast
cell activation
Julia Schanin1, Simon Gebremeskel1, Wouter Korver1, Rustom Falahati1, Melina Butuci1, Tatt Jhong Haw2, Prema M. Nair2, Gang Liu3,
Nicole G. Hansbro2,3, Philip M. Hansbro2,3, Erik Evensen4, Emily C. Brock1, Alan Xu1, Alan Wong1, John Leung1, Christopher Bebbington1,
Nenad Tomasevic1 and Bradford A. Youngblood1
In addition to their well characterized role in mediating IgE-dependent allergic diseases, aberrant accumulation and activation of
mast cells (MCs) is associated with many non-allergic inflammatory diseases, whereby their activation is likely triggered by non-IgE
stimuli (e.g., IL-33). Siglec-8 is an inhibitory receptor expressed on MCs and eosinophils that has been shown to inhibit IgE-mediated
MC responses and reduce allergic inflammation upon ligation with a monoclonal antibody (mAb). Herein, we evaluated the effects
of an anti-Siglec-8 mAb (anti-S8) in non-allergic disease models of experimental cigarette-smoke-induced chronic obstructive
pulmonary disease and bleomycin-induced lung injury in Siglec-8 transgenic mice. Therapeutic treatment with anti-S8 inhibited MC
activation and reduced recruitment of immune cells, airway inflammation, and lung fibrosis. Similarly, using a model of MC-
dependent, IL-33-induced inflammation, anti-S8 treatment suppressed neutrophil influx, and cytokine production through MC
inhibition. Transcriptomic profiling of MCs further demonstrated anti-S8-mediated downregulation of MC signaling pathways
induced by IL-33, including TNF signaling via NF-κB. Collectively, these findings demonstrate that ligating Siglec-8 with an antibody
reduces non-allergic inflammation and inhibits IgE-independent MC activation, supporting the evaluation of an anti-Siglec-8 mAb
as a therapeutic approach in both allergic and non-allergic inflammatory diseases in which MCs play a role.
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INTRODUCTION
Mast cells (MCs) are tissue-resident cells that have broad roles in
regulating acute and chronic tissue inflammation in a variety of
allergic, proliferative, and inflammatory diseases. Historically, MCs
have been associated with allergic inflammation, during which
their activation plays a critical role in driving type-2 inflammatory
diseases, such as eosinophilic asthma, atopic dermatitis, and
eosinophilic gastrointestinal diseases.1 Activation of MCs by
crosslinking the FcεRI via IgE induces rapid degranulation and
the release of preformed mediators, such as histamine, tumor
necrosis factor (TNF), and proteases, as well as the subsequent
release of de novo synthesized lipid mediators, cytokines, and
chemokines. Many of these substances attract or activate other
immune, epithelial, neuronal, and stromal cells that contribute to
acute and chronic allergic responses, such as vasodilation, plasma
extravasation, smooth muscle contraction, tissue eosinophilia, and
remodeling.1 In addition to allergic inflammation, MCs have been
implicated in non-allergic diseases, such as inflammatory bowel
disease, chronic obstructive pulmonary disease (COPD), type-2 low
asthma, idiopathic pulmonary fibrosis (IPF), and psoriasis.2–4 In
these disease settings, MCs are likely activated by inflammatory
mediators, such as cytokines, Toll-like receptor (TLR) ligands, and
neuropeptides.2,5
The alarmin cytokine interleukin (IL)−33 is one such mediator
that can directly activate MCs independent of IgE to promote non-
allergic inflammation, including neutrophil infiltration, tissue
remodeling, and fibrosis.6 IL-33 is released from cells following
tissue damage, stress, or cell death, and exerts its proinflammatory
biological functions through the ST2L receptor, which is present
on a subset of immune cells, including MCs and eosinophils.
Consistent with its role in tissue damage and fibrosis, increased
expression of IL-33 and ST2L have been observed in chronic non-
allergic airway diseases, such as COPD and IPF.7,8 COPD and IPF
are debilitating disorders of the lung characterized by chronic
airway inflammation and fibrosis that compromise tissue archi-
tecture, lung function, and gas exchange. In addition to increased
expression of IL-33/ST2L, MC numbers are elevated in COPD and
IPF patient lung tissue.3,4,7 Experimental animal models of COPD
and IPF further support the pathogenic role of MCs and IL-33/
ST2L.3,4,9,10 Indeed, mice deficient in MC tryptase have significantly
reduced airway inflammation, epithelial thickening, and emphy-
sematous damage in a cigarette smoke (CS)-induced experimental
COPD model.3,4 In addition, bleomycin (BLM)-induced lung fibrosis
and inflammation are attenuated in MC- or ST2-deficient mice or
with administration of a neutralizing IL-33 antibody.9,10 Collec-
tively, these data suggest that IL-33-mediated MC activation may
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play a role in the pathogenesis of chronic non-allergic airway
diseases and provide a rationale for targeting MCs as a potential
therapeutic strategy.
Sialic-acid-binding immunoglobulin-like lectin (Siglec)−8 is a
cell surface receptor that has emerged as a promising therapeutic
target for the treatment of allergic and inflammatory diseases.
Siglec-8 is an inhibitory receptor that is found selectively on
human MCs and eosinophils. Binding of a monoclonal antibody
(mAb) to Siglec-8 has been shown to induce death of cytokine-
primed eosinophils and inhibit IgE-mediated mast cell activa-
tion.11–14 In addition, treatment with an anti-Siglec-8 mAb (anti-
S8) has been shown to significantly reduce allergic gastrointestinal
inflammation in a novel Siglec-8 transgenic (tg) mouse model in
which the human Siglec-8 transgene is constitutively expressed on
murine mast cells, eosinophils, and to a lesser extent, basophils.15
Therapeutic modulation of MCs via targeting of Siglec-8 has also
been evaluated clinically with AK002, a humanized, nonfucosy-
lated IgG1 anti–Siglec-8 mAb that depletes eosinophils via
antibody-dependent cellular cytotoxicity (ADCC) and inhibits IgE-
dependent MC activation.11 Consistent with the critical role that
MCs play in allergic diseases and the inhibitory activity mediated
by Siglec-8, AK002 has demonstrated significant symptomatic
improvement in allergic diseases such as eosinophilic gastritis/
enteritis, chronic urticaria, and severe allergic conjunctivitis.16–18
While Siglec-8 engagement has been shown to inhibit IgE-driven
mast cell activation and allergic inflammation, such effects have not
yet been evaluated in non-allergic inflammation. In this study, we
demonstrate that anti-S8 treatment inhibits MC activation and
reduces immune cell infiltration, airway inflammation, and lung
fibrosis in non-allergic disease models of COPD and acute and
chronic BLM-induced lung fibrosis. We also provide evidence that
anti-S8 treatment inhibits IL-33-mediated MC activation and
neutrophil influx by globally modulating the MC transcriptome,
using a model of MC-driven, IL-33-induced inflammation. Lastly, we
show that anti-S8 reduces human neutrophil migration mediated by
IL-33-activated human peripheral blood derived MCs (hMCs).
Collectively, our findings demonstrate that anti-S8 treatment
reduces acute and chronic non-allergic inflammation and inhibits
IgE-independent MC activation, supporting clinical evaluation of
anti-Siglec-8 mAbs, such as AK002 as a therapeutic approach for
both allergic and non-allergic inflammatory diseases.
RESULTS
Therapeutic anti-Siglec-8 mAb treatment reduces chronic
inflammation in CS-induced experimental COPD
To evaluate the inhibitory activity of anti-S8 in chronic non-allergic
inflammation, we used a model of CS-induced experimental COPD
that has previously been shown to be partially MC-dependent and
have several hallmark features of human disease.3,4 COPD was
induced in Siglec-8 tg mice through nose-only exposure of CS for
12 weeks. Starting in week 8, when key features of COPD have
developed,3,4 mice were therapeutically dosed weekly with either
anti-S8 or isotype-matched control mAb until week 12 (Fig. 1a).
Mice were sacrificed and evaluated for markers of inflammation
and features of human COPD. To evaluate if anti-S8 treatment
decreased airway inflammation induced by CS, we assessed
pulmonary inflammation in bronchoalveolar lavage (BAL) fluid by
staining and differential enumeration of inflammatory cells at
week 12. Compared to mice exposed to normal air, CS-exposed
mice had significantly increased numbers of total leukocytes,
neutrophils, lymphocytes, and macrophages in BAL (Figs. 1b–d
and S1A). Therapeutic treatment with anti-S8 significantly
decreased total leukocytes induced by CS exposure, including
reductions in neutrophils and lymphocytes, but not macrophages,
compared to isotype control-treated mice. In addition, smoke
exposure increased the levels of chemokines associated with
immune cell infiltration, such as CXCL1 and CCL2, which were
significantly reduced in anti-S8-treated mice compared to isotype
control-treated mice (Fig. 1e, f). Consistent with a role for MCs in
experimental COPD, CS-exposed mice had increased numbers of
MCs as well as degranulating MCs in the lungs that were
significantly reduced in anti-S8 treated mice (Figs. 1g, h and S1B).
In addition, the level of MC protease-1 (MCPT1) was significantly
elevated in mice exposed to CS and decreased with anti-S8
treatment (Fig. 1i). Anti-S8 treatment also significantly reduced
histopathologic, airway, parenchymal, and vascular inflammation
scores induced by chronic CS exposure compared to isotype
control mAb-treated mice (Fig. 1j, k and S1C–E). These data
demonstrate that anti-S8-treatment reduces MC accumulation and
degranulation and suppresses non-allergic chronic inflammation
induced by CS.
We next investigated how the suppression of inflammation
impacted lung function in mice treated with anti-S8 or isotype
control mAb. Compared to mice exposed to normal air, CS
exposure significantly increased total lung capacity (TLC) that was
significantly reduced in anti-S8-treated mice (Fig. 1l). CS exposure
also significantly decreased tissue elastance (Fig. 1m) and forced
expiratory volume in 100 milliseconds (FEV100)/forced vital
capacity (FVC) ratio (representative of FEV1/FVC ratio in humans),
both of which were significantly improved in mice treated
therapeutically with anti-S8 (Figs. 1m and S1F). These data
demonstrate that therapeutic treatment with anti-S8 significantly
reduces chronic airway inflammation induced by long-term smoke
exposure and protects against CS-induced changes in lung
function.
Anti-Siglec-8 mAb treatment decreases acute and chronic BLM-
induced lung inflammation and fibrosis
The reduction in lung inflammation and tissue damage observed
in experimental COPD suggested that anti-S8 treatment may have
the potential to decrease tissue remodeling in non-allergic disease
settings. To investigate this further, we evaluated the activity of
anti-S8 in acute and chronic BLM-induced lung fibrosis models.
To evaluate the activity of anti-S8 in pulmonary fibrosis, we
used an acute model of BLM-induced lung injury. In this model,
lung inflammation peaks at ~3 days post intratracheal BLM
administration. Therefore we dosed mice at this time point with a
single injection of anti-S8 mAb (Fig. 2a). Compared to sham-
treated mice, BLM administration significantly increased airway
inflammation as evidenced by infiltration of leukocytes into the
BAL fluid, including neutrophils, monocytes, and macrophages,
whereas eosinophils were not detected (Fig. 2b–e, data not
shown). In addition, intratracheal BLM administration increased
cytokines and chemokines associated with immune cell recruit-
ment in the BAL fluid (Fig. 2f–h). One dose of anti-S8 significantly
suppressed BLM-induced infiltration of neutrophils, monocytes,
and macrophages as well as induction of cytokines and
chemokines associated with immune cell recruitment in BAL fluid,
such as IL-6, CXCL1, and IP-10 (Fig. 2b–h). Treatment with anti-S8
also resulted in a significant reduction in lung fibrosis as assessed
by Ashcroft score and decreased levels of collagen and TGFβ in
BAL (Fig. 2i–k). These data demonstrate that therapeutic treatment
with anti-S8 reduces lung inflammation and fibrosis in an acute
model of BLM-mediated lung injury.
To assess if the decrease in inflammation and fibrosis in mice
treated with anti-S8 was associated with reduced MC activity, we
quantified lung MC numbers and activation state by flow
cytometry and MCPT1 and MCPT4 levels in ex vivo cultured lung
tissue after acute BLM-injury. Lung MCs were identified as CD45+
7AAD− F480− CD11b− CD117+ FceRI+ and expressed Siglec-8
consistent with previous studies15 (Fig. 3a). Mice exposed to BLM
had increased numbers of MCs and activated MCs as assessed by
the degranulation marker CD63 (Fig. 3b, c). MCPT1 and MCPT4
levels were also significantly increased in lungs from BLM-
compared to sham-exposed mice (Fig. 3d, e). Treatment with
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anti-S8 significantly decreased MC numbers, activation state, and
tissue levels of MCPT1 and MCPT4, indicative of MC inhibition
(Fig. 3b–e). These data suggest the reduction of inflammation and
fibrosis in anti-S8 treated mice is associated with MC inhibition.
While single intratracheal administration of BLM induces acute
inflammation and lung fibrosis, it does not lead to cumulative
tissue damage and chronic inflammation. To evaluate anti-S8
treatment in a chronic model of lung inflammation and fibrosis,
we adapted a repetitive subcutaneous model where BLM is
administered every 2 days for 30 days.19 Anti-S8 was therapeu-
tically dosed on day 7 and weekly through day 28 (Fig. S2A).
Chronic subcutaneous injections of BLM significantly increased
neutrophils and macrophages in BAL fluid that were reduced in
anti-S8-treated mice (Fig. S2B, C). In addition, anti-S8 treatment
significantly reduced lung fibrosis as assessed by histology,
Ashcroft score, and lung tissue hydroxyproline levels (Fig. S2D,
E). Collectively, these data show that anti-S8 treatment inhibits MC
activity and reduces BLM-mediated inflammation and lung fibrosis
in acute and chronic non-allergic disease settings.
Siglec-8 mAb treatment reduces IL-33-mediated neutrophil and
monocyte infiltration through MC inhibition
We next determined whether anti-S8 treatment could directly
inhibit non-IgE-mediated MC activation along with suppressing
Fig. 1 Therapeutic treatment with Siglec-8 mAb reduces CS-induced airway inflammation and improves lung function in experimental
COPD. a Schematic of experimental COPD model. b Total leukocytes, c neutrophils, d lymphocytes, e CXCL1 levels, f and CCL2 levels in BAL
fluid from mice exposed to normal air (black), ISO+ smoke (gray) or anti-S8+ smoke (blue). Enumeration of g absolute lung MCs and
h degranulating MCs by chloroacetate esterase staining, and i quantification of MCPT1 in serum of mice exposed to normal air (black), ISO+
smoke (gray) or anti-S8+ smoke (blue). j, k Total histopathology score in lung sections or specifically in the airways. l, m Total lung capacity
and tissue elastance lung function parameters. Data are plotted as mean ± SEM (6–8 mice/group) *P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001 by one-way ANOVA with Tukey’s multiple-comparisons test. BAL bronchoalveolar lavage, q7D dosed every 7 days, COPD chronic
obstructive pulmonary disease, MCPT mast cell protease, TLC total lung capacity, ISO isotype control.
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non-allergic MC disease manifestations. To evaluate the inhibitory
activity of anti-S8 mAb in non-IgE-driven inflammation, we
adapted a mechanistic model of MC-dependent, IL-33-mediated
inflammation.6 In this model, intraperitoneal administration of IL-
33 induces a rapid neutrophil influx into the peritoneal cavity that
was shown to be completely dependent on peritoneal MCs and
ST2L using MC and ST2-deficient mice.6 To confirm that IL-33
administration could induce neutrophil recruitment in Siglec-8 tg
mice, we analyzed peritoneal immune cells 3 h after IL-33
injection. Consistent with previous findings, IL-33 dose-depen-
dently induced a significant neutrophil influx in the peritoneal
cavity that was not associated with a change in MC numbers in
Siglec-8 tg mice (Fig. S3A, B). IL-33 administration also dose-
dependently induced eosinophil and monocyte infiltration in the
peritoneal cavity (Fig. S3C, D), whereas other immune cells, such as
macrophages and lymphocytes remained unchanged (data not
shown).
We next evaluated IL-33-mediated leukocyte infiltration in the
peritoneal cavity following pre-dosing with anti-S8 or isotype
control mAb 1 h before IL-33 administration (Fig. 4a). As was
observed previously, IL-33 administration induced a significant
influx of neutrophils, monocytes, and eosinophils in the peritoneal
cavity compared to phosphate-buffered saline (PBS)-administered
control mice (Fig. 4b–e). Anti-S8 treatment significantly reduced
IL-33-induced neutrophil influx in the peritoneal cavity compared
to isotype control-treated mice. Similarly, anti-S8 treatment
significantly decreased IL-33-induced monocyte and eosinophil
infiltration. Consistent with previous findings, anti-S8 treatment
did not reduce mast cell numbers (Fig. 4f), suggesting the
reduction in IL-33-driven immune cell infiltration in the peritoneal
cavity is associated with mast cell inhibition, not apoptosis or
ADCC.
To determine whether the suppression of IL-33-driven inflam-
mation by anti-S8 treatment was solely due to Siglec-8-mediated
Fig. 2 Siglec-8 mAb treatment reduces acute BLM-induced lung inflammation and fibrosis. a Schematic of acute BLM-induced lung fibrosis
model. b Total leukocytes, c Neutrophils, d monocytes, e macrophages, f IL-6, g CXCL1, and h IP-10 in BAL fluid of sham (black), ISO+ acute
BLM (gray), or anti-S8+ acute BLM (blue) treated mice. i Ashcroft scores of lung fibrosis and BAL fluid levels of j collagen, and k TGFβ in sham
(black), ISO+ acute BLM (gray), or anti-S8+ acute BLM (blue) treated mice. Data are plotted as mean ± SEM (10–14 mice/group) and are
representative of at least three experiments. **P < 0.01; ***P < 0.001; ****P < 0.0001 by one-way ANOVA with Tukey’s multiple-comparisons test.
BAL bronchoalveolar lavage, BLM bleomycin, ISO isotype control.
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Fig. 4 Siglec-8 mAb treatment reduces IL-33-driven leukocyte infiltration in the peritoneal cavity through MC inhibition. a Schematic of
IL-33-induced inflammation model with Siglec-8 or isotype control mAb treatment. b Representative flow cytometry dot plots of neutrophils
and monocytes in the peritoneal cavity at 4 h in PBS, ISO+ IL-33, and anti-S8+ IL-33 treated groups. Percentage of c neutrophils,
d monocytes, e eosinophils, and f mast cells in the peritoneal cavity of mice treated with PBS (black), ISO+ IL-33 (gray), or anti-S8+ IL-33
(blue). The percentage of immune cells was derived from the CD45+ viable cell population. Data are plotted as mean ± SEM (11–12 mice/
group) and are representative of at least four experiments. *P < 0.05; ****P < 0.0001 by one-way ANOVA with Tukey’s multiple-comparisons
test. IP intraperitoneal, ISO isotype control, PBS phosphate-buffered saline.
Fig. 3 Siglec-8 mAb treatment decreases MC activity in acute BLM-mediated lung injury. a Flow cytometry gating strategy to identify MCs
in lungs from Siglec-8 tg mice stained with an anti-Siglec-8 mAb (blue) or FMO (gray). b Absolute MCs and c CD63+ MCs per lung determined
by flow cytometry in sham (black), ISO+ acute BLM (gray), or anti-S8+ acute BLM (blue) treated mice. d, e Levels of MCPT1 and MCPT4 from
overnight ex vivo lung culture in sham (black), ISO+ acute BLM (gray), or anti-S8+ acute BLM (blue) treated mice. Data are plotted as mean ±
SEM (six mice/group). **P < 0.01; ***P < 0.001 by one-way ANOVA with Tukey’s multiple-comparisons test. BLM bleomycin, FMO fluorescence
minus one, ISO isotype control, MCPT mast cell protease.
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MC inhibition, we depleted eosinophils in Siglec-8 tg mice using
an anti-CCR3 antibody. Anti-CCR3 mAb administration significantly
reduced eosinophils in the blood and spleen, consistent with
previous studies (Fig. S3E–H).20 Next, we depleted eosinophils
with anti-CCR3 and administered IL-33 intraperitoneally to ensure
IL-33-dependent neutrophil recruitment was not dependent on
eosinophils. Eosinophil depletion did not decrease IL-33-induced
neutrophil influx compared to mice with eosinophils (Fig. S3I).
These data suggest that eosinophils do not contribute to IL-33-
mediated neutrophil influx and strongly suggest that anti-S8
treatment significantly reduces acute IL-33-mediated leukocyte
infiltration in the peritoneal cavity by inhibiting MCs.
Siglec-8 mAb treatment decreases local and systemic cytokines/
chemokines induced by IL-33
Unlike IgE-mediated activation of MCs, IL-33 does not stimulate
degranulation, but instead, induces the secretion of cytokines and
chemokines from MCs.21 We next evaluated if the reduction in IL-
33-driven leukocyte infiltration observed in anti-S8-treated mice
was associated with a decrease in mediators that recruit these
immune cells. Consistent with the influx of immune cells,
intraperitoneal administration of IL-33 significantly increased the
levels of cytokines and chemokines associated with neutrophil,
monocyte, and eosinophil infiltration in the peritoneal cavity,
including IL-6, CCL2, CXCL2, CXCL1, TNF, IL-13, CCL3, and CCL4
(Figs. 5a–f and S4A, B). Treatment with anti-S8 significantly
decreased IL-33-induced cytokines and chemokines compared to
isotype control mAb mice. Since many of these mediators can be
produced by multiple types of immune cells, we cultured
peritoneal MCs in vitro and found that stimulation with IL-33
produced a similar profile of cytokines and chemokines as in
peritoneal lavage in vivo (Fig. S4C). These data are consistent with
ST2L (IL-33R) being mainly found on mast cells in the peritoneal
cavity, (Fig. S4D) and suggest that MCs are the initial source of
these mediators upon IL-33 administration.
Having established peritoneal levels of these IL-33-induced
cytokines and chemokines, we next evaluated IL-33-induced systemic
effects by analyzing mediators in serum. IL-33 administration also
increased serum levels of cytokines and chemokines that were
significantly reduced in anti-S8 treated mice, including the monocyte-
and neutrophil-attracting chemokines, CCL2 and CXCL1 (Fig. 5g, h).
These data demonstrate that anti-S8 treatment significantly reduces
local and systemic IL-33-induced cytokines and chemokines and
suggest that MCs are a major target cell of IL-33.
Siglec-8 mAb treatment modulates the transcriptome of MCs to
suppress IL-33-mediated inflammation
To better characterize anti-S8-induced inhibition of IL-33-activated
MCs and to gain insight into the mechanism of MC inhibition, we
assessed the transcriptional profile of isolated peritoneal MCs after
IL-33 administration in vivo. Following the induction of IL-33-
driven inflammation, peritoneal MCs were FACS-sorted from
individual mice based on CD117 and FcεRI expression and
subjected to high resolution gene-expression analysis by RNA-
seq (Figs. 6a and S5A). Consistent with a highly enriched MC
population, we found a significant correlation between MC-
specific genes in our dataset with the previously published
transcriptional signature of tissue-resident MCs, including Tpsab1,
Fig. 5 Siglec-8 mAb treatment decreases local and systemic cytokines and chemokines induced by IL-33. a–f Levels of IL-6, CCL2, CXCL2,
CXCL1, TNF, and IL-13 in the peritoneal cavity and (G-H) CCL2 and CXCL1 in the serum of mice treated with PBS (black), ISO+ IL-33 (gray) or
anti-S8+ IL-33 (blue). Data are plotted as mean ± SEM (9–10 mice/group) and are representative of at least four experiments. *P < 0.05; **P <
0.01; ***P < 0.001; ****P < 0.0001 by one-way ANOVA with Tukey’s multiple-comparisons test. ISO isotype control, PBS phosphate-buffered
saline.
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Tpsab2, Cma1, and Mrgprb2 (Fig. S5B).22 To identify gene
expression modulated by IL-33 administration, we performed a
comparison of mice treated with IL-33 vs. PBS control for 3 h. As
expected, IL-33 treatment significantly changed the transcriptional
profile of peritoneal MCs (Fig. S5C). Using enrichment analysis, we
analyzed differentially expressed genes to identify hallmark gene
sets overrepresented in MCs activated by IL-33. These gene sets
participated in mTORC signaling, TNF signaling through NF-κB,
unfolded protein response, and IL-6 via STAT3 signaling (Fig. S5D),
consistent with previously published data.23 These data demon-
strate that IL-33 directly activates and modulates the transcrip-
tome of peritoneal MCs in vivo to drive inflammation.
Next, we assessed the effect of anti-S8 treatment on IL-33-
induced changes in the MC transcriptome by comparing mice
treated with IL-33 and isotype control mAb versus IL-33 and anti-
S8 (Fig. 6a). We identified 498 differentially expressed genes that
were up- or downregulated upon IL-33 administration and
significantly changed after anti-S8 treatment (Fig. 6b). Many of
these genes were associated with MC activity and function, such
as Hdc, Tnf, Slc6a19, Nfkb1, Il1f9, and Tpsab1. Principal component
analysis further highlighted the differences between IL-33-
activated MCs and anti-S8-inhibited MCs and the similarities
between anti-S8-inhibited and PBS control MCs (Fig. 6c). To
analyze pathways associated with anti-S8-mediated inhibition of
IL-33-activated MCs, we used enrichment analysis to identify top
differentially expressed hallmark gene sets that were over-
represented among the genes upregulated in IL-33-activated
MCs and downregulated after anti-S8 treatment. Anti-S8 treat-
ment downregulated IL-33-induced genes that encoded for critical
signaling pathways of IL-33 activation, including unfolded protein
response, TNF signaling via NF-κB, mTORC1 signaling, IL-2 and
STAT5 signaling, and PI3K and AKT signaling (Fig. 6d).
To confirm the differential gene expression observed in our
RNA-seq dataset, we performed qPCR on FACS-sorted peritoneal
Fig. 6 Siglec-8 mAb negatively modulates the IL-33-activated MC transcriptome in vivo. a Schematic of in vivo RNA-seq experimental
design. b Heatmap of the top differentially expressed genes (absolute log2Fold >0.4, unadjusted p < 0.05) from FACS-sorted peritoneal MCs
after in vivo administration of IL-33+ ISO (left), IL-33 + anti-S8 (middle), or PBS (right). Each column represents transcriptome data from
individual mice (n= 5/group). c Principal component analysis of genes displayed in the heatmap from ISO+ IL-33 (gray), anti-S8+ IL-33 (blue),
or PBS control mice (black). d Hallmark enrichment analysis of anti-S8 downregulated genes that were activated with IL-33. e Confirmatory
qPCR analysis of genes identified in RNA-seq dataset from FACS-sorted peritoneal MCs treated with IL-33+ ISO (gray) or anti-S8 (blue). Dashed
line represents normalized gene expression of PBS control peritoneal MCs. For panel e, data are plotted as mean ± SEM (n= 4/group; three
mice pooled/sample). **P < 0.01 by Mann–Whitney U test. FACS fluorescence-activated cell sorting, ISO isotype control, PBS phosphate-
buffered saline, SEM standard error of the mean.
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MCs and found that anti-S8 treatment similarly decreased the
expression of a subset of genes induced by IL-33 compared to
isotype control mAb treatment (Fig. 6e). Lastly, we examined
differential gene expression of peritoneal MCs treated with an
isotype control mAb or anti-S8 that were not exposed to IL-33 to
evaluate gene expression changes that could be related to Siglec-
8-mediated inhibition in non-activated MCs. Interestingly, anti-S8
treatment increased the expression of other genes associated with
inhibitory functions, including Tmem176a, Ticam2, Tifab, and
Unc93b, suggesting Siglec-8-mediated inhibition of MCs may
utilize additional inhibitory receptors (Fig. S5E). These data
suggest that anti-S8 treatment globally modulates the transcrip-
tome of peritoneal MCs to suppress IL-33-mediated inflammation
through MC inhibition.
Siglec-8 mAb treatment reduces IL-33-mediated neutrophil
migration by inhibiting human MCs
Since Siglec-8 is natively expressed on human MCs, we sought to
extend the relevance of our data from murine models to humans
using mature human MCs (hMCs) derived from peripheral blood
progenitors.22,24 Consistent with the known expression pattern of
Siglec-8, fully mature hMCs expressed Siglec-8 (Fig. 7a). To
determine whether endogenous Siglec-8 expression levels were
sufficient to mediate inhibition in these cells, we activated hMCs
through the IgE pathway using an anti-FcεRI antibody in the
presence of anti-S8 or an isotype control mAb. Treatment with
anti-S8 significantly reduced hMC activation as evidenced by
decreased CD63 expression (Fig. 7b), suggesting Siglec-8 is
functional in these cells.
To assess the effects of anti-S8 treatment on IL-33-mediated
hMC activation, we adapted a human neutrophil migration assay
previously shown to be mediated by IL-33-stimulated MCs.6
Neutrophil migration toward supernatants from IL-33-activated
hMCs was significantly increased compared to supernatants from
unstimulated hMCs (Fig. 7c). Directly stimulating neutrophils with
the chemoattractant IL-8 significantly increased neutrophil migra-
tion to a similar extent as supernatant from IL-33-activated hMCs,
suggesting hMCs produce neutrophil chemotactic factors upon IL-
33 stimulation (Fig. 7c). Next we assessed if anti-S8 could affect
neutrophil migration induced by IL-33 activated hMCs. Super-
natant from IL-33-activated hMCs treated with anti-S8 for 6 h
showed significantly less neutrophil migration and IL-8 levels
compared to supernatant from isotype control-treated hMCs
activated with IL-33 (Fig. 7d, e). These data suggest that anti-S8
inhibits IL-33-mediated hMC activation and further highlight MCs
as important orchestrators of immune cell recruitment upon
stimulation.
DISCUSSION
MCs are key effector cells that regulate acute and chronic
inflammatory responses through the release of preformed and
de novo synthesized mediators in response to a diverse array of
activating stimuli, including IgE, IgG, cytokines, neuropeptides,
and TLR ligands. Aberrant accumulation and activation of MCs is
associated with a substantial number of allergic, inflammatory,
and proliferative diseases, whereby MCs are thought to be key
drivers of inflammation, tissue damage, and remodeling. Siglec-8
has emerged as a promising therapeutic target for allergic and
inflammatory diseases due to both its selective expression on MCs
and eosinophils and its inhibitory activity. Previous studies
showed that anti-S8 mAbs directly inhibit IgE-mediated MC
activation in vitro and that this inhibition requires the immunor-
eceptor tyrosine-based inhibitory motif (ITIM) domain.24 To study
Fig. 7 Siglec-8 mAb treatment decreases human neutrophil migration induced by IL-33 activated hMCs. a Dot plot showing the
percentage of mature hMCs at the end of the differentiation period and the expression of Siglec-8 on mature hMCs (blue) compared to a
fluorescence minus one (FMO) negative control (gray). b The percentage of CD63 positive hMCs after 20min of stimulation with anti-FcεRI
(5 μg/mL) in the presence of ISO (gray) or anti-S8 (blue) compared to non-stimulated cells (black). c The percentage of neutrophil migration
induced by media alone (black) or supernatants collected from hMCs alone (dark gray), hMCs stimulated with IL-33 (light gray), or direct IL-8
neutrophil stimulation (red). d The percentage of neutrophil migration induced by media alone (black) or supernatants from hMCs alone (dark
gray), hMCs stimulated with IL-33+ ISO (light gray), or +anti-S8 (blue). e Normalized level of IL-8 in hMC supernatant stimulated with IL-33+
ISO (light gray) or anti-S8 (blue). Data are plotted as mean ± SEM (3–5 human donors/group) and are representative of at least two
experiments. For panels d and e, neutrophil migration and IL-8 levels were normalized to ISO-treated hMCs. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001 by one-way ANOVA with Tukey’s multiple-comparisons test or by Mann–Whitney U test. ISO isotype control, hMCs human
peripheral blood derived mast cells, SEM standard error of the mean.
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the activity of anti-Siglec-8 mAb in non-allergic murine models, we
used a previously described Siglec-8 tg mouse because of the
disparities between human Siglec-8 and its functional paralog in
mice, Siglec-F, most notably, the lack of expression of Siglec-F on
murine mast cells.12,15
Chronic non-allergic airway diseases, including COPD, IPF, and
type-2 low asthma, are major respiratory disorders that have
limited treatment options. These diseases are associated with
increased tissue and BAL neutrophils, whereas chronic allergic
airway diseases, such as type-2-high asthma, are characterized by
elevated eosinophils. While most current and emerging biologic
therapies for asthma specifically target eosinophils and type-2
cytokines, there is a significant unmet need for effective
treatments for non-allergic chronic neutrophilic airway
diseases.25,26 Notably, MCs have been shown to be elevated in
patients with chronic non-allergic airway diseases, and mice
deficient in MCs have reduced inflammation and tissue remodel-
ing in models of COPD and BLM-induced fibrosis, suggesting MCs
contribute to pathogenesis.
Treatment with anti-S8 significantly reduced infiltration of
immune cells into the airways induced by CS or BLM, including
neutrophils, monocytes, macrophages, and lymphocytes, com-
pared to mice receiving an isotype-matched control mAb. The
reduction in immune cell infiltrate was consistent with decreases
in cytokines and chemokines that recruit these immune cells in
anti-S8 treated mice. The significant decrease in CS and BLM-
induced inflammation by anti-S8 treatment was associated with
reduced MC numbers and activation, consistent with the
inhibitory activity of these mAbs. In addition to reducing airway
inflammation, therapeutic anti-S8 treatment decreased histo-
pathologic changes in lung tissue induced by CS, and attenuated
BLM-mediated lung fibrosis. These data support previous studies
showing that MCs can drive fibrosis and tissue remodeling
through the recruitment of immune cells and production of pro-
fibrotic mediators, such as TGFβ, CCL2, tryptase, and IL-13.27 We
did not detect eosinophils in the BAL fluid in the experimental
COPD or BLM models. The exact role of eosinophils in these
models has not been extensively studied and remains
controversial.28,29 For example, IL-5-deficient mice that lack
eosinophils still develop BLM-mediated fibrosis, suggesting
eosinophils do not play a major role in BLM-induced lung
injury.29,30 Nevertheless, since anti-S8 also has anti-eosinophil
activity, we cannot completely exclude the possibility that some of
the activity seen with anti-S8 treatment could be due to the
reduction of those cells.
To directly evaluate the inhibitory activity of anti-S8 in non-IgE-
mediated MC activation, we used a MC-dependent, IL-33-driven
model of inflammation. Anti-S8 treatment significantly reduced IL-
33-mediated neutrophil, monocyte, and eosinophil infiltration and
decreased IL-33-induced cytokines and chemokines by directly
inhibiting MCs. Notably, the reduction in IL-33-driven inflamma-
tion by anti-S8 was not associated with a decrease in MC numbers
which is consistent with an inhibitory, rather than apoptosis-
inducing effect of ligating Siglec-8 on MCs.11,13,15 Transcriptomic
profiling of peritoneal MCs activated by IL-33 and dosed with anti-
S8 further confirmed anti-S8-mediated MC inhibition. Anti-S8
treatment significantly and globally modulated IL-33-induced
gene expression, highlighting the broad inhibitory activity of
Siglec-8. While our data do not identify the exact signaling
pathway that leads to anti-S8-mediated MC inhibition, they do
confirm that anti-S8 can inhibit non-IgE-mediated MC activation
and provide insight into the mechanism of inhibition.
The ability of Siglec-8 to inhibit IL-33-mediated MC activation is
intriguing because ITIM-containing receptors are mainly thought to
recruit immunoreceptor tyrosine-based activation motif (ITAM)-
bearing receptors, such as FcεRI to induce MC inhibition. Previous
studies evaluating CD33 (Siglec-3)-mediated MC inhibition showed
that antigenic liposomes with CD33 ligand prevented IgE-
mediated MC activation by recruiting CD33 to the IgE/FcεRI
complex.31 Similarly, strategies using bispecific antibodies to co-
ligate inhibitory receptors (FcγRIIB or CD300a) with either IgE or
FcεRI also demonstrated that coupling the inhibitory and activating
receptor is required for IgE-mediated MC inhibition.32–34 However,
studies evaluating Siglec activity on immune cells other than MCs
have shown that Siglecs can inhibit TLR activation in a MyD88-
dependent manner.35,36 Indeed, Siglec-E in the mouse attenuates
LPS/TLR4-mediated activation by decreasing NF-κB activation and
the secretion of proinflammatory mediators.35 Interestingly, IL-33
also activates NF-κB signaling in MCs via the classical MyD88/IRAK/
TRAF6 module,37 suggesting Siglec-8 may use a similar mechanism
as Siglec-E to mediate inhibition. In support of this, transcriptomic
profiling of peritoneal MCs that were treated with anti-S8 showed
significantly increased expression of genes associated with TLR
inhibition and MyD88 signaling, including Unc93b1, Ticam2, and
Tifab.38–42 Moreover, TICAM2 and TIFAB have been shown to
interact directly with the MyD88/IRAK/TRAF6 complex to regulate
TLR signaling.38,39 Future studies will focus on further characteriz-
ing the intracellular pathways induced by anti-S8 ligation that lead
to Siglec-8-mediated inhibition in MCs.
Currently, limited therapeutic options are available in the clinic
to treat MC-driven disorders.2 Most MC-stabilizing drugs and H1
antagonists have minimal activity against MCs, and many patients
become refractory over time, underscoring the importance for
new therapeutics.2 Anti-IgE monoclonal antibodies, e.g. omalizu-
mab, have been shown to be effective in some allergic diseases,
including chronic urticaria, eosinophilic asthma, and nasal
polyposis. However, since MCs express multiple activating
receptors, and these biologics target only IgE-mediated MC
activation, they are likely to be less effective in complex allergic
and non-IgE-driven diseases.2,43,44 Targeting Siglec-8 with the anti-
S8 mAb, AK002, represents a new therapeutic approach that has
shown promising effects in early clinical studies in patients with
eosinophilic and mast cell-driven disorders. The data reported
here further expand on the activity of anti-S8 mAbs for treatment
of non-allergic diseases that involve MCs and support the
evaluation of AK002 as a therapeutic approach in both allergic
and non-allergic inflammatory diseases.
METHODS
Mice
Siglec-8 tg mice were generated as previously described.6 Female
and male Siglec-8 tg mice were maintained at Taconic Biosciences
(Germantown, NJ, USA) and used at 8–12 weeks of age. All animal
experiments were done under an IACUC-approved protocol. For
all studies, animals were formally randomized, technicians were
blinded to treatment groups.
Model of cigarette-smoke-induced experimental COPD and
assessment of inflammation and lung function
Siglec-8 tg mice (6–8 weeks of age) were simultaneously exposed
to CS (twelve 3R4F reference cigarettes (University of Kentucky,
Lexington, Ky) twice per day, five times per week for 12 weeks)
using a custom-designed and purpose-built nose-only, directed
flow inhalation and smoke-exposure system (CH Technologies,
Westwood, NJ) housed in a fume and laminar flow hood as
previously described.3,4,45,46 Each exposure lasted 75min on week
8, mice were dosed intraperitoneally at 5 mg/kg once a week with
either an anti-Siglec-8 mIgG1 mAb (2E2 clone, Allakos, Inc) or
isotype-matched control mIgG1 mAb (Biolegend) until week 12.
Airway inflammation was assessed by means of differential
enumeration of inflammatory cells in BAL fluid.4,45 Lungs were
perfused, inflated, embedded in paraffin, and sectioned. Histolo-
gical scoring, airway, vascular, and parenchymal inflammation
were assessed by counting the number of inflammatory cells in a
minimum of four randomized fields of H&E-stained lung sections
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as previously described.47 To assess lung function, mice were
anaesthetized using ketamine (100 mg kg−1) and xylazine (10 mg
kg−1), tracheas cannulated and attached to Buxco® Forced
Maneuvers apparatus (DSI, St. Paul, MN, USA) to assess total lung
capacity (TLC).4 FlexiVent apparatus (FX1 System; SCIREQ, Mon-
treal, Canada) was used to assess FVC and elastance (tidal volume
8mL kg−1, respiratory frequency 450 breaths min−1).4 All experi-
ments were approved by the University of Newcastle animal ethics
committee. Measurements were done without the opportunity
for bias.
Acute model of IL-33-induced peritoneal inflammation
Siglec-8 tg mice (6–10 weeks old) were injected intraperitoneally
with PBS or 10–50 ng of recombinant mouse IL-33 (Biolegend) as
previously described.6 Three hours later cells within the peritoneal
cavity were collected by lavage with RPMI and immediately
analyzed by flow cytometry. An anti-Siglec-8 mIgG1 mAb (2E2
clone, Allakos, Inc) or isotype-matched control mIgG1 mAb
(Biolegend) were administered intraperitoneally at 5 mg/kg 1 h
before IL-33 administration.
Statistics
To determine statistical significance, nonparametric Mann–Whitney
U test, unpaired two-tailed t test, two-tailed t test with Holm–Šídák’s
posttest, or one-way ANOVA with Tukey’s posttest for multiple
comparisons was performed using Prism (GraphPad Software). A P-
value of 0.05 or less was considered significant.
ACKNOWLEDGEMENTS
We thank Drs. Bruce S. Bochner and Robert P. Schleimer for their critical review and
feedback on the manuscript and Ingrid Koo, Ph.D. for writing support. Research was
funded by Allakos, Inc. PMH is funded by a Fellowship and grants from the National
Health and Medical Research Council (NHMRC) of Australia (1079187, 1175134, and
1023131) and the Australian Research Council (150102153). P.M.H. and N.G.H. are
supported by the University of Technology Sydney. Research was funded by Allakos,
Inc. PMH is funded by a Fellowship and grants from the National Health and Medical
Research Council (NHMRC) of Australia (1079187, 1175134, and 1023131) and the
Australian Research Council (150102153). P.M.H. and N.G.H. are supported by the
University of Technology Sydney.
AUTHOR CONTRIBUTIONS
B.A.Y., C.B., N.T., P.M.H., and J.S. designed the experiments. J.S., S.G., W.K., R.F., M.B.,
T.J.H., N.G.H., G.L., E.C.B., A.X., A.W., and B.A.Y. performed the experiments. J.L.
developed and provided reagents. E.E. analyzed NGS data. B.A.Y., S.G., W.K., and J.S.
wrote the manuscript.
ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41385-020-00336-9)
contains supplementary material, which is available to authorized users.
Competing interests: J.S., S.G., W.K., R.F., M.B., E.C.B., A.X., A.W., J.L., C.B., N.T., and B.A.Y.
are or were employees of Allakos and/or own stock options in Allakos. Other authors
have nothing to declare.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Galli, S. J. & Tsai, M. IgE and mast cells in allergic disease. Nat. Med. 18, 693–704
(2012).
2. Siebenhaar, F., Redegeld, F. A., Bischoff, S. C., Gibbs, B. F. & Maurer, M. Mast cells
as drivers of disease and therapeutic targets. Trends Immunol. 39, 151–162 (2018).
3. Hansbro, P. M. et al. Importance of mast cell Prss31/transmembrane tryptase/
tryptase-gamma in lung function and experimental chronic obstructive pul-
monary disease and colitis. J. Biol. Chem. 289, 18214–18227 (2014).
4. Beckett, E. L. et al. A new short-term mouse model of chronic obstructive pul-
monary disease identifies a role for mast cell tryptase in pathogenesis. J. Allergy
Clin. Immunol. 131, 752–762 (2013).
5. Yu, Y., Blokhuis, B. R., Garssen, J. & Redegeld, F. A. Non-IgE mediated mast cell
activation. Eur. J. Pharmacol. 778, 33–43 (2016).
6. Enoksson, M. et al. Intraperitoneal influx of neutrophils in response to IL-33 is
mast cell-dependent. Blood 121, 530–536 (2013).
7. Xia, J. et al. Increased IL-33 expression in chronic obstructive pulmonary disease.
Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L619–L627 (2015).
8. Lee, J.-U. et al. Upregulation of interleukin-33 and thymic stromal lymphopoietin
levels in the lungs of idiopathic pulmonary fibrosis. BMC Pulm. Med. 17, 39 (2017).
9. Li, D. et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of
alternatively activated macrophages and innate lymphoid cells in mice. J. Allergy
Clin. Immunol. 134, 1422–1432.e11 (2014).
10. Reber, L. L., Daubeuf, F., Pejler, G., Abrink, M. & Frossard, N. Mast cells contribute
to bleomycin-induced lung inflammation and injury in mice through a chymase/
mast cell protease 4-dependent mechanism. J. Immunol. 192, 1847–1854 (2014).
11. Youngblood, B. A. et al. AK002, a humanized sialic acid-binding immunoglobulin-
like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxi-
city against human eosinophils and inhibits mast cell-mediated anaphylaxis in
mice. Int. Arch. Allergy Immunol. 180, 91–102 (2019).
12. Bochner, B. S. ‘Siglec’ting the allergic response for therapeutic targeting. Glyco-
biology 26, 546–552 (2016).
13. Yokoi, H. et al. Inhibition of FcepsilonRI-dependent mediator release and calcium
flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8
engagement. J. Allergy Clin. Immunol. 121, 499–505 (2008).
14. O’Sullivan, J. A., Chang, A. T., Youngblood, B. A. & Bochner, B. S. Eosinophil and
mast cell Siglecs: from biology to drug target. J. Leukoc. Biol. https://doi.org/
10.1002/JLB.2MR0120-352RR (2020).
15. Youngblood, B. A. et al. Siglec-8 antibody reduces eosinophils and mast cells in a
transgenic mouse model of eosinophilic gastroenteritis. JCI Insight 4, pii: 126219
(2019).
16. Maurer, M. Efficacy and safety data of AK002, an anti-Siglec-8 monoclonal anti-
body, in patients with multiple forms of uncontrolled chronic urticaria (CU):
results from an open-label phase 2a study. in European Academy of Allergy and
Clinical Immunology (EAACI) Annual Meeting LBOA1701 (EAACI, 2019).
17. Siebenhaar, F. et al. Safety and efficacy data of AK002, an anti-Siglec-8 mono-
clonal antibody, in patients with indolent systemic mastocytosis (ISM): results
from a first-in-human, open-label phase 1 study. in European Academy of Allergy
and Clinical Immunology (EAACI) Annual Meeting LBTP1937 (EAACI, 2019).
18. Tauber, J. et al. AK002, an anti-Siglec-8 monoclonal antibody, in severe allergic
conjunctivitis: results from an open-label phase 1b study (KRONOS). in American
Academy of Ophthalmology (AAO) Annual Conference P0067 (AAO, 2019).
19. Yoshizaki, A. et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/
Th17 cell balance in a bleomycin-induced scleroderma model. J. Immunol. 185,
2502–2515 (2010).
20. Shen, H., Xu, F., Zhang, G., Wang, S. & Xu, W. CCR3 monoclonal antibody inhibits
airway eosinophilic inflammation and mucus overproduction in a mouse model
of asthma. Acta Pharmacol. Sin. 27, 1594–1599 (2006).
21. Enoksson, M. et al. Mast cells as sensors of cell injury through IL-33 recognition. J.
Immunol. 186, 2523–2528 (2011).
22. Dwyer, D. F., Barrett, N. A. & Austen, K. F. Expression profiling of constitutive mast
cells reveals a unique identity within the immune system. Nat. Immunol. 17,
878–887 (2016).
23. Chhiba, K. D., Hsu, C.-L., Berdnikovs, S. & Bryce, P. J. Transcriptional heterogeneity
of mast cells and basophils upon activation. J. Immunol. 198, 4868–4878 (2017).
24. Saito, H., Kato, A., Matsumoto, K. & Okayama, Y. Culture of human mast cells from
peripheral blood progenitors. Nat. Protoc. 1, 2178–2183 (2006).
25. Esteban-Gorgojo, I., Antolin-Amerigo, D., Dominguez-Ortega, J. & Quirce, S. Non-
eosinophilic asthma: current perspectives. J. Asthma Allergy 11, 267–281 (2018).
26. Gabryelska, A., Kuna, P., Antczak, A., Bialasiewicz, P. & Panek, M. IL-33 mediated
inflammation in chronic respiratory diseases-understanding the role of the
member of IL-1 superfamily. Front. Immunol. 10, 692 (2019).
27. Overed-Sayer, C., Rapley, L., Mustelin, T. & Clarke, D. L. Are mast cells instrumental
for fibrotic diseases? Front. Pharmacol. 4, 174 (2013).
28. Huaux, F. et al. Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in
bleomycin-induced lung injury and fibrosis. Am. J. Pathol. 167, 1485–1496 (2005).
29. Huaux, F. et al. Eosinophils and T lymphocytes possess distinct roles in
bleomycin-induced lung injury and fibrosis. J. Immunol. 171, 5470–5481 (2003).
30. Hao, H., Cohen, D. A., Jennings, C. D., Bryson, J. S. & Kaplan, A. M. Bleomycin-
induced pulmonary fibrosis is independent of eosinophils. J. Leukoc. Biol. 68,
515–521 (2000).
31. Duan, S. et al. CD33 recruitment inhibits IgE-mediated anaphylaxis and desen-
sitizes mast cells to allergen. J. Clin. Invest 129, 1387–1401 (2019).
A Siglec-8 mAb suppresses non-allergic inflammation
J Schanin et al.
10
Mucosal Immunology _#####################_
32. Kraft, S. & Kinet, J.-P. New developments in FcepsilonRI regulation, function and
inhibition. Nat. Rev. Immunol. 7, 365–378 (2007).
33. Bachelet, I., Munitz, A. & Levi-Schaffer, F. Abrogation of allergic reactions by a
bispecific antibody fragment linking IgE to CD300a. J. Allergy Clin. Immunol. 117,
1314–1320 (2006).
34. Zellweger, F. et al. A novel bispecific DARPin targeting FcgammaRIIB and
FcepsilonRI-bound IgE inhibits allergic responses. Allergy 72, 1174–1183 (2017).
35. Boyd, C. R. et al. Siglec-E is up-regulated and phosphorylated following lipopo-
lysaccharide stimulation in order to limit TLR-driven cytokine production. J.
Immunol. 183, 7703–7709 (2009).
36. Pillai, S., Netravali, I. A., Cariappa, A. & Mattoo, H. Siglecs and immune regulation.
Annu. Rev. Immunol. 30, 357–392 (2012).
37. Pinto, S. M. et al. A network map of IL-33 signaling pathway. J. Cell Commun.
Signal. 12, 615–624 (2018).
38. Varney, M. E. et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis
through derepression of Toll-like receptor-TRAF6 signaling. J. Exp. Med. 212,
1967–1985 (2015).
39. Seya, T., Oshiumi, H., Sasai, M., Akazawa, T. & Matsumoto, M. TICAM-1 and TICAM-
2: toll-like receptor adapters that participate in induction of type 1 interferons. Int.
J. Biochem. Cell Biol. 37, 524–529 (2005).
40. Ortiz, M. et al. The evolutionary history of the CD209 (DC-SIGN) family in humans
and non-human primates. Genes Immun. 9, 483–492 (2008).
41. Majer, O., Liu, B., Kreuk, L. S. M., Krogan, N. & Barton, G. M. UNC93B1 recruits
syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. Nature 575,
366–370 (2019).
42. Schleimer, R. P. et al. Effects of dexamethasone on mediator release from human lung
fragments and purified human lung mast cells. J. Clin. Invest. 71, 1830–1835 (1983).
43. Cardet, J. C. & Casale, T. B. New insights into the utility of omalizumab. J. Allergy
Clin. Immunol. 143, 923–926.e1 (2019).
44. Dellon, E. S. et al. Efficacy and safety of AK002 in adult patients with active
eosinophilic gastritis and/or eosinophilic gastroenteritis: primary results from a
randomized, double-blind placebo-controlled phase 2 trial (ENIGMA Study). in
American College of Gastroenterology (ACG) Annual Scientific Meeting 36 (ACG,
2019).
45. Haw, T. J. et al. A pathogenic role for tumor necrosis factor-related apoptosis-
inducing ligand in chronic obstructive pulmonary disease. Mucosal Immunol. 9,
859–872 (2016).
46. Fricker, M. et al. Chronic cigarette smoke exposure induces systemic hypoxia that
drives intestinal dysfunction. JCI insight 3, e94040 (2018).
47. Horvat, J. C. et al. Neonatal chlamydial infection induces mixed T-cell responses
that drive allergic airway disease. Am. J. Respir. Crit. Care Med. 176, 556–564
(2007).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2020
A Siglec-8 mAb suppresses non-allergic inflammation
J Schanin et al.
11
Mucosal Immunology _#####################_
